Slide 1: Aritinercept (AUR200) Results from a Phase 1 Study
Aritinercept (AUR200) A Dual BAFF/APRIL Inhibitor for the Potential Treatment of Autoimmune Diseases Results from a Phase 1 Study June 30, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management
Slide 3: Aritinercept (AUR200) Is a Dual BAFF/APRIL Inhibitor
Aritinercept (AUR200) Is a Dual BAFF/APRIL Inhibitor • Aritinercept contains a BCMA-engineered extracellular binding domain optimized for APRIL BAFF superior affinity to BAFF and APRIL (others use TACI-engineered extracellular binding domain) Engineered extracellular domain of BCMA receptor − BCMA h
Slide 4: Role of BAFF and APRIL
Role of BAFF and APRIL • BAFF and APRIL are important cytokines that regulate B cell survival and differentiation, whose targets are expressed on B cells at different stages of B cell development a • Targeting both BAFF and APRIL depletes a broader set of B cells, including plasma cells, than target
Slide 5: Aritinercept Is a High Affinity Dual BAFF/APRIL Inhibitor
Aritinercept Is a High Affinity Dual BAFF/APRIL Inhibitor a BAFF APRIL Drug (Sponsor) Compared to Compared to Kd (pM) Kd (pM) Aritinercept Aritinercept Aritinercept 117 N/A 25 N/A (Aurinia) Atacicept 919 7.9x 67 2.7x (Vera) Telitacicept 616 5.3x 82 3.3x (RemeGen) Aritinercept has high binding affini
Slide 6: Potently Inhibits BAFF- and APRIL-Mediated B Cell Proliferation
Aritinercept Potently Inhibits BAFF- and APRIL-Mediated B Cell Proliferation a B Cell Proliferation in the Presence of BAFF B Cell Proliferation in the Presence of APRIL Relative Luminescence Units (RLUs) Relative Luminescence Units (RLUs) Aritinercept Aritinercept Atacicept Atacicept Telitacicept T
Slide 7: Reduced Immunoglobulins in Non-Human Primates
Aritinercept Reduced Immunoglobulins in Non-Human Primates a IgA IgM IgG 20% 20% 20% 0% 0% 0% Mean Change from Baseline -20% -20% -20% -40% -40% -40% -60% -60% -60% -80% -80% -80% Mean IgA reductions Mean IgM reductions Mean IgG reductions Dosing Dosing Dosing of up to 43% of up to 76% of up to 67%
Slide 8: Aritinercept SAD Study Design
Aritinercept SAD Study Design Screening (up to 5 weeks), In-Clinic Phase (1 week) and Out-Patient Visits (13 weeks) Dose Level 6 (n=8 Healthy Subjects) Screening 300 mg SC Placebo n=6 n=2 Dose Level 5 (n=8 Healthy Subjects) Screening 225 mg SC Placebo n=6 n=2 Dose Level 4 (n=21 Healthy Subjects) Scr
Slide 9: Safety Summary
Safety Summary • Aritinercept was well tolerated at all dose levels tested • No treatment-related Grade ≥3 adverse events a • No treatment-related serious adverse events (SAEs) a • No discontinuations due to treatment-related adverse events • Adverse events that occurred in more than one subject inc
Slide 10: Pharmacokinetics Summary
Pharmacokinetics Summary 30 Aritinercept Serum Concentration a 25 25 mg SC 20 75 mg SC 150 mg SC (μg/mL) 225 mg SC 15 300 mg SC 10 5 0 0 7 14 21 28 Study Day A half-life of 6-8 days after a single dose in the target dose range was observed a Geometric mean 10
Slide 11: Single Doses Led to Robust and Long-Lasting Reductions in Immunoglobulins
Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins in Humans IgA IgM IgG 20% 20% 20% Mean Change from Baseline 0% 0% 0% -20% -20% -20% -40% -40% -40% Mean IgA reductions Mean IgM reductions Mean IgG reductions of up to 48% of up to 55% of up to 20% -60% -60% -6
Slide 12: Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA Reductions in IgA a 20% Mean % Change Drug Mean Change from Baseline from Baseline in IgA 0% (Sponsor) at Day 28 a Aritinercept -48% (Aurinia) -20% Povetacicept -43% (Vertex) Sibeprenlimab -40% -41% (Otsuka) Atacicept -10% (Vera) -60% Telitacic
Slide 13: Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM Reductions in IgM a 20% Mean % Change Drug Mean Change from Baseline from Baseline in IgM 0% (Sponsor) at Day 28 a Aritinercept -55% (Aurinia) -20% Povetacicept -52% (Vertex) Sibeprenlimab -40% -39% (Otsuka) Atacicept -17% (Vera) -60% Telitacic
Slide 14: Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG
Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG Reductions in IgG a 20% Mean % Change Drug Mean Change from Baseline from Baseline in IgG 0% (Sponsor) at Day 28 a Aritinercept -20% (Aurinia) -20% Povetacicept -19% (Vertex) Sibeprenlimab -40% -13% (Otsuka) Atacicept N/A b (Vera) -60% Telitaci
Slide 15: Summary and Next Steps
Summary and Next Steps • Aritinercept was well tolerated at all dose levels tested • Single doses of aritinercept led to robust and long-lasting reductions in immunoglobulins supportive of once-monthly dosing • Aurinia plans to initiate clinical studies of aritinercept in at least two autoimmune dis
Slide 16: © Aurinia Pharmaceuticals Inc., 2025. All rights reserved. Trademarks and logos are the property
© Aurinia Pharmaceuticals Inc., 2025. All rights reserved. Trademarks and logos are the property of Aurinia Pharmaceuticals Inc.